iEthico Raises £1.2M to Use AI to Predict and Prevent Drug Shortages

iEthico, a UK health technology company, has raised £1.2 million to develop its AI-powered platform for predicting and managing pharmaceutical drug shortages. The company is building software that applies machine learning to pharmaceutical supply chain data to identify the early warning signals of impending drug shortages — enabling manufacturers, wholesalers, hospital pharmacies, and regulatory bodies to take preventative action before a shortage impacts patient care.

Drug shortages are a persistent and serious public health problem. In any given month, dozens of medicines are in short supply across the UK and global pharmaceutical markets, affecting everything from common antibiotics and anaesthetics to specialist oncology drugs and rarely-used products for which no alternative exists. Shortages can arise from manufacturing failures at a single-source facility, raw material supply chain disruptions, demand spikes driven by seasonal illness or emerging treatment guidelines, regulatory actions against suppliers, or the commercial decisions of pharmaceutical companies to exit low-margin markets. Their consequences range from treatment delays and the need to switch patients to less suitable alternatives, to in the most serious cases, direct patient harm when critical medicines are unavailable.

Current shortage management is predominantly reactive: a shortage is identified when supply falls below demand, at which point the response is constrained by whatever inventory remains in the system and by the time required to identify and authorise alternative supply. iEthico's approach is to shift this to proactive: by aggregating and analysing supply chain data from across the pharmaceutical distribution network — including manufacturing capacity signals, procurement data, regulatory filings, and historical shortage patterns — the platform can identify the combination of factors that typically precede a shortage and alert stakeholders while there is still time to act. This might enable a hospital pharmacy to build safety stock of a drug that is showing early supply risk, or a wholesaler to diversify its supplier base for a product with concentrated manufacturing risk, before the shortage materialises.

The funding will be used to develop the platform's predictive models, build data partnerships with pharmaceutical supply chain stakeholders, and establish commercial relationships with the NHS and private sector pharmacy organisations that bear the operational burden of shortage management.

Sources

• iEthico — company website